FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1654518051> ?p ?o ?g. }

• W1654518051 abstract "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PAFibroblast growth factor homologous factors (FHF1-4) belong to the FGF family involved in prostate cancer. Based on the cBioPortal database (MSKCC, Cancer Cell 2010), FGF13 (FHF2), one of the FHF subfamily members, shows altered mRNA expression in prostate cancer. In this study we aimed to analyze FGF13 expression and functions in prostate cancer.We collected prostate cancer specimens from 234 patients who underwent radical prostatectomy in Turku University Hospital. Frozen tissue was used for qRT-PCR to measure FGF13 mRNA in 76 samples in which glandular or cancer area covered at least 50% of the specimen (non-cancer, n = 31; cancer, n = 45). Tissue microarrays (TMA) containing cancer (n = 152) and adjacent non-cancer (n = 203) samples were examined for FGF13 protein by immunohistochemical staining. Total FGF13 staining score of each TMA core was calculated using HistoScore system. Chi-square test, Kaplan-Meier and Cox proportional hazards regression model were used to analyze the association between FGF13 staining and clinicopathological parameters. Immunofluorescence was used to detect FGF13 localization in prostate cancer cells in vitro.The level of FGF13 mRNA was significantly higher in cancer tissues than in non-cancer tissues (p = 0.0028). FGF13 mRNA levels did not show significant association with the Gleason score, pathologic stage, pre-operation PSA value or PSA failure time. In the TMA study, cancer cells showed weak, moderate or strong cytoplasmic staining for FGF13 in over 99% of the samples whereas luminal epithelial cells were positive in only 53% of the adjacent non-cancer samples. Correspondingly, the cytoplasmic staining of FGF13 presented higher scores in cancer than in non-cancer areas (p<0.001). Moreover, nuclear staining of FGF13 was also observed, and it was more frequent in cancer samples compared to non-cancer samples (59% and 12%, respectively). Especially, basal cells showed positive immunoreactivity sporadically in non-cancer tissues. Only very weak or negative immunostaining of FGF13 was found in stromal cells but interestingly, prominent expression of FGF13 was observed in mononuclear cells.In terms of time to biochemical recurrence after prostatectomy, patients with high FGF13 cytoplasmic staining had a shorter PSA failure free time compared to patients who had lower cytoplasmic FGF13 expression (p = 0.009). Multivariate analysis revealed that high cytoplasmic FGF13 staining (HR = 3.76, 95%CI [1.5-9.3], p = 0.004) was significantly associated with a shorter PSA failure time. Immunofluorescence staining in PC3M cells showed that FGF13 was located to the cytoplasm and nuclei.Overall, our study demonstrates, for the first time, expression and location of FGF13 protein in prostate cancer and suggests that FGF13 could have prognostic value in primary prostate cancer.Citation Format: Lan Yu, Miikka Tuomala, Mervi Toriseva, Teresa Elo, Johanna Tuomela, Heikki Seikkula, Martti Nurmi, Peter Bostrom, Tuomas Mirtti, Kalle Alanen, Markku Kallajoki, Pirkko Harkonen. High expression of fibroblast growth factor 13 (FGF13) in prostate cancer is associated with a shortened time to biochemical recurrence after radical prostatectomy. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3454. doi:10.1158/1538-7445.AM2015-3454" @default.
• W1654518051 created "2016-06-24" @default.
• W1654518051 creator A5013653434 @default.
• W1654518051 creator A5014782116 @default.
• W1654518051 creator A5025250184 @default.
• W1654518051 creator A5025900152 @default.
• W1654518051 creator A5027010797 @default.
• W1654518051 creator A5040800642 @default.
• W1654518051 creator A5041638532 @default.
• W1654518051 creator A5066264896 @default.
• W1654518051 creator A5067115547 @default.
• W1654518051 creator A5088342842 @default.
• W1654518051 creator A5089377917 @default.
• W1654518051 creator A5048717249 @default.
• W1654518051 date "2015-08-01" @default.
• W1654518051 modified "2023-09-26" @default.
• W1654518051 title "Abstract 3454: High expression of fibroblast growth factor 13 (FGF13) in prostate cancer is associated with a shortened time to biochemical recurrence after radical prostatectomy" @default.
• W1654518051 doi "https://doi.org/10.1158/1538-7445.am2015-3454" @default.
• W1654518051 hasPublicationYear "2015" @default.
• W1654518051 type Work @default.
• W1654518051 sameAs 1654518051 @default.
• W1654518051 citedByCount "0" @default.
• W1654518051 crossrefType "proceedings-article" @default.
• W1654518051 hasAuthorship W1654518051A5013653434 @default.
• W1654518051 hasAuthorship W1654518051A5014782116 @default.
• W1654518051 hasAuthorship W1654518051A5025250184 @default.
• W1654518051 hasAuthorship W1654518051A5025900152 @default.
• W1654518051 hasAuthorship W1654518051A5027010797 @default.
• W1654518051 hasAuthorship W1654518051A5040800642 @default.
• W1654518051 hasAuthorship W1654518051A5041638532 @default.
• W1654518051 hasAuthorship W1654518051A5048717249 @default.
• W1654518051 hasAuthorship W1654518051A5066264896 @default.
• W1654518051 hasAuthorship W1654518051A5067115547 @default.
• W1654518051 hasAuthorship W1654518051A5088342842 @default.
• W1654518051 hasAuthorship W1654518051A5089377917 @default.
• W1654518051 hasConcept C121608353 @default.
• W1654518051 hasConcept C126322002 @default.
• W1654518051 hasConcept C142724271 @default.
• W1654518051 hasConcept C143998085 @default.
• W1654518051 hasConcept C2776235491 @default.
• W1654518051 hasConcept C2779466945 @default.
• W1654518051 hasConcept C2780192828 @default.
• W1654518051 hasConcept C502942594 @default.
• W1654518051 hasConcept C71924100 @default.
• W1654518051 hasConcept C96232424 @default.
• W1654518051 hasConceptScore W1654518051C121608353 @default.
• W1654518051 hasConceptScore W1654518051C126322002 @default.
• W1654518051 hasConceptScore W1654518051C142724271 @default.
• W1654518051 hasConceptScore W1654518051C143998085 @default.
• W1654518051 hasConceptScore W1654518051C2776235491 @default.
• W1654518051 hasConceptScore W1654518051C2779466945 @default.
• W1654518051 hasConceptScore W1654518051C2780192828 @default.
• W1654518051 hasConceptScore W1654518051C502942594 @default.
• W1654518051 hasConceptScore W1654518051C71924100 @default.
• W1654518051 hasConceptScore W1654518051C96232424 @default.
• W1654518051 hasLocation W16545180511 @default.
• W1654518051 hasOpenAccess W1654518051 @default.
• W1654518051 hasPrimaryLocation W16545180511 @default.
• W1654518051 hasRelatedWork W1439248239 @default.
• W1654518051 hasRelatedWork W1488263247 @default.
• W1654518051 hasRelatedWork W1935995766 @default.
• W1654518051 hasRelatedWork W1982989784 @default.
• W1654518051 hasRelatedWork W2019939907 @default.
• W1654518051 hasRelatedWork W2042121341 @default.
• W1654518051 hasRelatedWork W2091376345 @default.
• W1654518051 hasRelatedWork W2136316648 @default.
• W1654518051 hasRelatedWork W2139095395 @default.
• W1654518051 hasRelatedWork W2258204764 @default.
• W1654518051 hasRelatedWork W2369951041 @default.
• W1654518051 hasRelatedWork W2588492615 @default.
• W1654518051 hasRelatedWork W3028602236 @default.
• W1654518051 hasRelatedWork W3029042719 @default.
• W1654518051 hasRelatedWork W3029561389 @default.
• W1654518051 hasRelatedWork W3030483121 @default.
• W1654518051 hasRelatedWork W3032293134 @default.
• W1654518051 hasRelatedWork W3085127516 @default.
• W1654518051 hasRelatedWork W3134434546 @default.
• W1654518051 hasRelatedWork W853358315 @default.
• W1654518051 isParatext "false" @default.
• W1654518051 isRetracted "false" @default.
• W1654518051 magId "1654518051" @default.
• W1654518051 workType "article" @default.